A study to determine whether drug Nitazoxanide is useful in uncomplicated amoebic liver abscess

Evaluating the efficacy of Nitazoxanide in uncomplicated amoebic liver abscess

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/01/017249

Enrollment

Registered

2019-01-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A064- Amebic liver abscess

Interventions

Intervention1: Nitazoxanide: 500 mg BD per oral for 10 days Control Intervention1: Metronidazole: 800 mg TDS per oral for 10 days

Eligibility

Inclusion criteria

Inclusion criteria: Clinical, biochemical and ultrasonography features suggestive of liver abscess

Exclusion criteria

Exclusion criteria: patients with organ failure (indicative of more serious disease), patients in danger of imminent rupture, severe cardiac, pulmonary, renal disease, immunodeficiency status and not giving written consent

Design outcomes

Primary

Measure	Time frame
Clinical response: resolution of clinical symptoms of invasive amoebiasis (fever, abdominal pain and hepatomegaly) and normalisation of leukocytosisTimepoint: End of treatment (Day 10)	—

Secondary

Measure	Time frame
Decrease in abscess volume seen on USGTimepoint: From baseline to day 10 to 3rd month	—

Countries

India

Contacts

Public ContactVasudha Goel

SMS Medical College and Hospital

pa894@yahoo.co.in9829966420

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 22, 2026